Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India Jun 8, 2021
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19 May 3, 2021
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Mar 24, 2021
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion… Feb 26, 2021